Mexicor in the combination therapy of chronic heart failure and Type 2 diabetes mellitus

The study included 60 patients, aged 45-65 years, with Functional Class II-III chronic heart failure (CHF) in early post-infarction period and Type 2 diabetes mellitus (DM-2). The participants were randomised into two groups (n=30 for each group). In the main group, Mexicor (0,4 g/d) was added to the standard CHF treatment. The treatment phase was 16 weeks. It was shown that a cytoprotector Mexicor, as a part of combination therapy in CHF patients with DM-2, reduced CHF severity, demonstrated antianginal effect, and improved quality of life. Adding Mexicor to the combination therapy of CHF and DM-2 also improved diastolic function, reduced the number of patients with adverse types of cardiac remodelling, beneficially affected lipid and carbohydrate metabolism parameters, significantly reduced the severity of insulin resistance and chronic inflammation syndrome, and demonstrated a marked antioxidant effect. Moreover, 16-week Mexicor therapy, as an addition to the standard CHF and DM-2 treatment, had beneficial effects on alanine and aspartate aminotransferase activity.